Stryker shares hit new lifetime high | MassDevice.com On Call
April 7, 2014 by Arezu Sarvestani
MASSDEVICE ON CALL — Medtech titan Stryker hit a new lifetime high on Friday with shares rising to $84.85 apiece.
The share spiked after a gradual incline over the course of Thursday, April 3, peaking in the late morning on Friday before settling down to close at $82.60, a 1.8% drop on the day. Read more
TriVascular Technologies sets price range for $98M IPO
April 4, 2014 by Brad Perriello
TriVascular Technologies said it could raise as much as $98 million from its planned initial public offering after setting the per-share price range at $13-$15.
That would set the top end of the 6.5-million-share offering at $97.5 million, or $84.5 million at the low end. Read more
Deerfield raises $1.6B healthcare fund
April 8, 2014 by Brad Perriello
Deerfield Management Co. said it raised a fund aimed at healthcare investments that’s worth $1.6 billion.
Deerfield Private Design Fund III is "designed to provide flexible private financing to healthcare companies," according to a press release. Read more
Vital Therapies lowers the bar with 2nd IPO try
April 7, 2014 by Brad Perriello
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million. Read more
Delcath Systems tanks following reverse stock split
April 9, 2014 by Arezu Sarvestani
Shares of Delcath dropped more than 18% by the early afternoon today after the company proceeded with a 1-to-16 reverse stock split.
The slide unraveled the stock’s gradual rise over the course of 2014, leaving shares down nearly 6% for the year. Shares had briefly traded as high as $6.72 apiece in March. Read more
